Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entecavir vs Lamivudine in Japanese Adults with Chronic Hepatitis B
NCT01022801Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2003
- Primary completion
- Mar 2005
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of entecavir in Chronic Hepatitis B (CHB) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Mean change from baseline in HBV DNA levels at 22 weeks. Started Aug 2003; status: completed.
02
Drugs
entecavir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT01022801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01022801.